Compare BMI & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMI | ICUI |
|---|---|---|
| Founded | 1905 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 4.0B |
| IPO Year | 1994 | 1995 |
| Metric | BMI | ICUI |
|---|---|---|
| Price | $131.25 | $163.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 8 |
| Target Price | $156.56 | ★ $193.38 |
| AVG Volume (30 Days) | ★ 365.9K | 218.4K |
| Earning Date | 10-22-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | 13.24 | ★ 100.62 |
| EPS | 1.95 | ★ 1.96 |
| Revenue | N/A | ★ $2,231,262,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.86 | $4.44 |
| P/E Ratio | ★ $67.93 | $83.65 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $112.09 | $113.37 |
| 52 Week High | $204.00 | $192.85 |
| Indicator | BMI | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 52.37 | 53.36 |
| Support Level | $123.99 | $152.02 |
| Resistance Level | $138.27 | $167.67 |
| Average True Range (ATR) | 4.35 | 4.15 |
| MACD | 0.69 | 0.75 |
| Stochastic Oscillator | 71.40 | 73.81 |
Badger Meter is a provider of water management solutions. The company's solutions encompass measurement and control hardware, connectivity and communication, data visualization and software. Badger Meter has global operations, with the vast majority of revenue derived from the US.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.